Allergan (NYSE:AGN) is one of the many biotech stocks that has been beaten down in the last one and a half year. In this article I will indicate 4 reasons why I think the company and the stock can perform well in the future.
Reason #1: Diversified sources of revenue and rich pipeline
One of the characteristics that I like in Allergan is its rich portfolio of drugs. As we can see....More>>>
A recent column addressed the idea of moving in retirement. To be more specific: What are the pros and cons of retiring in a college town?
The advantages, at first blush, are clear: a stimulating atmosphere, opportunities for continuing education, a diverse population, a stable economy (for the most part), and, frequently, lots of restaurants, shopping and cultural events. That said,....More>>>
Among the technological fantasies offered by science fiction, “Star Trek’s” holodeck is one of the most intriguing. The holodeck shows realistic 3D images of anything you desire, whether it’s a gladiator contest, a crowded city street, a ski race, a mountaintop aerie, you name it.
The 25th century has arrived early. Science fiction is quickly becoming science fact,....More>>>
Puma Biotechnology (NASDAQ:PBYI) ended the day down 13.8% after Roche (NASDAQOTH:RHHBY) reported that its rival breast cancer drug, Perjeta, had passed its phase 3 trial, dubbed “Aphinity.”
Image source: Getty Images.
In Roche’s trial, patients either took Perjeta and Herceptin with chemotherapy or just Herceptin with chemotherapy,....More>>>
One of the smaller details of Trumpcare, the redacted version of Obamacare, is the elimination of a tax imposed on manufacturers of medical devices. While the fate of pre-existing conditions has been hogging the spotlight in recent days, this particular tax and its future could have an impact on companies like Ventripoint Diagnostics (OTCMKTS: VPTDF TSE:VPT), and other small cap biotech....More>>>
Healthcare spending is on track to make up nearly 20% of U.S. GDP by 2025, according to the U.S. Centers for Medicare & Medicaid Services (CMS).
That’s one of the reasons we expect the biotech stock we’re showing you today to double in price by 2020.
Another catalyst for this top biotech stock is the aging baby boomer generation. There are currently 76.5 million....More>>>
Starting with a simple tweet on September 21st, 2015, Hillary Clinton has been pummeling Biotech stocks since her Presidential Campaign first began. In fact, Clinton has caused dramatic drops in the iShares Nasdaq Biotechnology ETF (IBB) at least three times in the past 14 months. The thought of Clinton winning the presidency, and the corresponding assault on the Biotech sector,....More>>>
Like most of you, I don’t like to lose money. So you might be wondering why I was so quick to scoop up more shares of Gilead Sciences (NASDAQ:GILD) stock after its latest earnings report. After all, management shared a forecast for 2017 hepatitis C antiviral sales 39% lower than 2016 figures, and that’s at the high end of the provided range.
Before you assume I’ve completely....More>>>
Last year, Gilead Sciences (NASDAQ:GILD) managed a feat that very few of its peers ever have (or probably ever will): It shed a staggering $40 billion in value without a single top-selling drug going off patent.
GILD Market Cap data by YCharts.
In fact, the biotech actually launched multiple new products last year, such as the HIV medsOdefsey and Descovy, along with the latest addition....More>>>
William Patalon III
In a Private Briefing report in late July, we told you that tiny biotech Inovio Pharmaceuticals Inc. (Nasdaq: INO) had dosed its first patient in a Phase I clinical study to evaluate its synthetic vaccine for the Zika virus.
The announcement caught my eye for several reasons…
This is premium content for Private Briefing subscribers only.